90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease
Open Access
- 8 July 2014
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 167 (2), 207-213
- https://doi.org/10.1111/bjh.13021
Abstract
90Y‐ibritumomab‐tiuxetan (90YIT) was used as a first‐line therapy for patients with early‐stage follicular lymphoma (FL) or marginal zone B‐cell lymphoma (MZL). Thirty‐one patients were treated, with an overall 3‐month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow‐up of 56 months, ten patients (32%) had disease relapse or progression. The progression‐free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non‐bulky disease, although they did not reach statistical significance. Grade 3–4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early‐stage low‐grade B‐cell lymphomas. Bulky disease did not adversely affect tumour response.Keywords
This publication has 12 references indexed in Scilit:
- 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent TrialJournal of Clinical Oncology, 2013
- Moving Radioimmunotherapy Forward for Follicular LymphomaJournal of Clinical Oncology, 2013
- 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical TrialJournal of Clinical Oncology, 2013
- Long‐term outcomes for patients with limited stage follicular lymphomaCancer, 2010
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular LymphomaJournal of Clinical Oncology, 2008
- Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's LymphomaCancer Biotherapy & Radiopharmaceuticals, 2007
- Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment GroupJournal of Clinical Oncology, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphomaAnnals of Oncology, 1996